Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAOB | P27338 | 6/20 | 0.64 |
| ▸ | MAOA | P21397 | 3/20 | 0.64 |
| ▸ | SCN9A | Q15858 | 1/20 | 0.64 |
| ▸ | MEN1 | O00255 | 1/20 | 0.61 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.61 |
| ▸ | CD274 | Q9NZQ7 | 1/20 | 0.58 |
| ▸ | BCHE | P06276 | 1/20 | 0.56 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7396648 | 1.00 | MAOB (0.64) | MAOBMAOASCN9AMEN1KMT2A | |
| SCHEMBL7390171 | 0.88 | SCN9A (0.70) | MAOBMAOASCN9ABCHE | |
| SCHEMBL7390166 | 0.88 | SCN9A (0.70) | MAOBMAOASCN9ABCHE | |
| SCHEMBL966003 | 0.88 | MAOB (0.62) | MAOBMAOASCN9A | |
| SCHEMBL965324 | 0.88 | MAOB (0.83) | MAOBMAOASCN9A | |
| SCHEMBL964409 | 0.88 | MAOB (0.83) | MAOBMAOASCN9A | |
| SCHEMBL963797 | 0.88 | MAOB (0.83) | MAOBMAOASCN9A | |
| SCHEMBL4456855 | 0.87 | MAOB (0.74) | MAOBMAOASCN9ABCHE | |
| SCHEMBL1070615 | 0.87 | MAOB (0.74) | MAOBMAOASCN9ABCHE | |
| SCHEMBL7403715 | 0.87 | MAOB (0.74) | MAOBMAOASCN9ABCHE |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 17 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20080132567-A1 | Alpha-Aminoamide Derivatives Useful in the Treatment of Lower Urinary Tract Disorders | NEWRON PHARMACUETICALS S.P.A (IT) | 2008-06-05 | — | — | US | claimed |
| CN-1956714-A | Alpha-aminoamide derivatives for the treatment of lower urinary tract disorders | NEWRON PHARM SPA (IT) | 2007-05-02 | — | — | CN | claimed |
| WO-2005070405-A1 | ALPHA-AMINOAMIDE DERIVATIVES USEFUL IN THE TREATMENT OF LOWER URINARY TRACT DISORDERS | NEWRON PHARMACEUTICALS S.P.A. (IT) | 2005-08-04 | — | — | WO | claimed |
| EP-1557166-A1 | Alpha-aminoamide derivatives useful in the treatment of lower urinary tract disorders | Newron Pharmaceuticals S.p.A. (IT) | 2005-07-27 | — | — | EP | claimed |
| US-7718815-B2 | Alpha-aminoamide derivatives useful in the treatment of lower urinary tract disorders | NEWRON PHARMACEUTICALS S.P.A. (IT) | 2010-05-18 | — | — | US | disclosed |
| CN-100584323-C | Alpha-aminoamide derivatives useful in the treatment of lower urinary tract disorders | NEWRON PHARM SPA | 2010-01-27 | — | — | CN | disclosed |
| US-20080132567-A1 | Alpha-Aminoamide Derivatives Useful in the Treatment of Lower Urinary Tract Disorders | NEWRON PHARMACUETICALS S.P.A (IT) | 2008-06-05 | — | — | US | disclosed |
| CN-1956714-A | Alpha-aminoamide derivatives for the treatment of lower urinary tract disorders | NEWRON PHARM SPA (IT) | 2007-05-02 | — | — | CN | disclosed |
| WO-2005070405-A1 | ALPHA-AMINOAMIDE DERIVATIVES USEFUL IN THE TREATMENT OF LOWER URINARY TRACT DISORDERS | NEWRON PHARMACEUTICALS S.P.A. (IT) | 2005-08-04 | — | — | WO | disclosed |
| EP-1557166-A1 | Alpha-aminoamide derivatives useful in the treatment of lower urinary tract disorders | Newron Pharmaceuticals S.p.A. (IT) | 2005-07-27 | — | — | EP | disclosed |
| US-5502079-A | TREATMENT OF CENTRAL NERVOUS SYSTEM DISORDERS | FARMITALIA CARLO ERBA S.R.L. (IT) | 1996-03-26 | — | — | US | disclosed |
| US-5391577-A | Active on central nervous system; antiepileptic agents | FARMITALIA CARLO ERBA S R L (IT) | 1995-02-21 | — | — | US | disclosed |
| EP-0400495-B1 | N-phenylalkyl substituted alpha-amino carboxamide derivatives and process for their preparation. | ERBA CARLO SPA (IT) | 1993-11-03 | — | — | EP | disclosed |
| US-5236957-A | Antiepileptic agents | FARMITALIA CARLO ERBA SRL (IT) | 1993-08-17 | — | — | US | disclosed |
| EP-0426816-A1 | N-PHENYLALKYL SUBSTITUTED $g(a)-AMINO CARBOXAMIDE DERIVATIVES AND PROCESS FOR THEIR PREPARATION | FARMITALIA CARLO ERBA S.r.l. (IT) | 1991-05-15 | — | — | EP | disclosed |
| EP-0400495-A1 | N-phenylalkyl substituted alfa-amino carboxamide derivatives and process for their preparation | FARMITALIA CARLO ERBA S.r.l. (IT) | 1990-12-05 | — | — | EP | disclosed |
| WO-1990014334-A1 | N-PHENYLALKYL SUBSTITUTED α-AMINO CARBOXAMIDE DERIVATIVES AND PROCESS FOR THEIR PREPARATION | FARMITALIA CARLO ERBA S.R.L. (IT) | 1990-11-29 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080132567-A1 | Alpha-Aminoamide Derivatives Useful in the Treatment of Lower Urinary Tract Disorders | AADAT, BCAT2, DNPEP | MAOB 362/4885MAOA 295/4885SCN9A 2174/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.